Thiazolidinedione bioactivation: A comparison of the bioactivation potentials of troglitazone, rosiglitazone, and pioglitazone using stable isotope-labeled analogues and liquid chromatography tandem mass spectrometry

Chemical Research in Toxicology

Volumn 19, Issue 8, 2006, Pages 1106-1116

  Alvarez Sánchez, Rubén ^a   Montavon, François ^a   Hartung, Thomas ^a   Pähler, Axel ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; CARBON 13; DISULFIDE; GLUTATHIONE; ISOTOPE; NITROGEN 15; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE;

ANIMAL CELL; CARBON NUCLEAR MAGNETIC RESONANCE; CONFERENCE PAPER; DRUG ACTIVATION; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; NONHUMAN; OXIDATIVE STRESS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT; TANDEM MASS SPECTROMETRY;

ANIMALS; CHROMANS; CHROMATOGRAPHY, LIQUID; GLUTATHIONE; HUMANS; HYPOGLYCEMIC AGENTS; ISOTOPE LABELING; MASS SPECTROMETRY; MICROSOMES, LIVER; RATS; THIAZOLIDINEDIONES;

EID: 33748656068     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx050353h     Document Type: Conference Paper

References (35)

1. Saltiel, A. R., and Olefsky, J. M. (1996) Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45, 1661-1669.
2. Kohlroser, J., Mathai, J., Reichheld, J., Banner, B. F., and Bonkovsky, H. L. (2000) Hepatotoxicity due to troglitazone: Report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. J. Gastroenterol. 95, 272-276.
3. Menon, K. V. N., Angulo, P., and Lindor, K. D. (2001) Severe cholestatic hepatitis from troglitazone in a patient with nonalcoholic steatohepatitis and diabetes mellitus. Am. J. Gastroenterol. 96, 1631-1634.
4. Smith, M. T. (2003) Mechanisms of troglitazone hepatotoxicity. Chem. Res. Toxicol. 16, 679-687.
5. Tettey, J. N., Maggs, J. L., Rapeport, W. G., Pirmohamed, M., and Park, B. K. (2001) Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivo. Chem. Res. Toxicol. 14, 965-974.
6. Kawai, K., Kawasaki-Tokui, Y., Odaka, T., Tsuruta, F., Kazui, M., Iwabuchi, H., Nakamura, T., Kinoshita, T., Ikeda, T., Yoshioka, T., Komai, T., and Nakamura, K. (1997) Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. Arzneimit1elforschung 47, 356-368.
7. Shen, Z., Reed, J. R., Creighton, M., Liu, D. Q., Tang, Y. S., Hora, D. F., Feeney, W., Szewczyk, J., Bakhtiar, R., Franklin, R. B., and Vincent, S. H. (2003) Identification of novel metabolites of pioglitazone in rat and dog. Xenobiotica 33, 499-509.
8. Kassahun, K., Pearson, P. G., Tang, W., McIntosh, I., Leung, K., Elmore, C., Dean, D., Wang, R., Doss, G., and Baillie. T. A. (2001) Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol. 14, 62-70.
9. Prabhu, S., Fackett, A., Lloyd, S., McClellan, H. A., Terrell, C. M., Silber, P. M., and Li, A. P. (2002) Identification of glutathione conjugates of troglitazone in human hepatocytes. Chem.-Biol. Interact. 142, 83-97.
10. Soglia, J. R., Harriman, S. P., Zhao, S., Barberia, J., Cole, M. J., Boyd, J. G., and Contillo, L. G. (2004) The development of a higher throughput reactive intermediate screening assay incorporating microbore liquid chromatography-micro-electrospray ionization-tandem mass spectrometry and glutathione ethyl ester as an in vitro conjugating agent. J. Pharm. Biomed. Anal 36, 105-116.
11. Forman, L. M., Simmons, D. A., and Diamond, R. H. (2000) Hepatic failure in a patient taking rosiglitazone. Ann. Intern. Med. 132, 118-121.
12. May, L. D., Lefkowitch, J. H., Kram, M. T., and Rubin, D. E. (2002) Mixed hepatocellular-cholestatic liver injury after pioglitazone therapy. Ann. Intern. Med. 136, 449-452.
13. Sahi, J., Black, C. B., Hamilton, G. A., Zheng, X., Jolley, S., Rose, K. A., Gilbert, D., Leduyse, E. L., and Sinz, M. W. (2003) Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metab. Dispos. 31, 439-446.
14. Kiyota, Y., Kondo, T., Maeshiba, Y., Hashimoto, A., Yamashita, K., Yoshimura, Y., Motohashi, M., and Tanayama, S. (1997) Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 47, 22-28.
15. Baughman, T. M., Graham, R. A., Wells-Knecht, K., Silver, I. S., Tyler, L. O., Wells-Knecht, M., and Zhao, Z. (2005) Metabolic activation of pioglitazone identified from rat and human liver microsomes and freshly isolated hepatocytes. Drug Metab. Dispos. 33, 733-738.
16. Cox, P. J., Ryan, D. A., Hollis, F. J., Harris, A. M., Miller, A. K., Vousden, M., and Cowley, H. (2000) Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 28, 772-780.
17. Rettenmeier, A. W., Gordon, W. P., Barnes, H., and Baillie, T. A. (1987) Studies on the metabolic fate of valproic acid in the rat using stable isotope techniques. Xenobiotica 17, 1147-1157.
18. Taylor, E. W., Jia, W., Bush, M., and Dollinger, G. D. (2002) Accelerating the drug optimization process: Identification, structure elucidation, and quantification of in vivo metabolites using stable isotopes with LC/MSn and the chemiluminescent nitrogen detector. Anal. Chem. 74, 3232-3238.
19. Wolff, H.-P., and Witte, E.-C. (1997) New process for preparing troglitazone. International patent application, publication no. WO 97/ 43283.
20. Adiyaman, M., Guner, D., Yurdakul, A., and Ridvanoglu, N. (2003) A process for the production of phenyl ethers. International patent application, publication no. WO 2004/000810 A1.
21. Cantello, B. C., Cawthorne, M. A., Cottam, G. P., Duff, P. T., Haigh, D., Hindley, R. M., Lister, C. A., Smith, S. A., and Thurlby, P. L. (1994) [[omega-(Heterocyclylamino)alkoxylbenzyl]-2,4-thiazolidinediones as potent antihyperglycemic agents. J. Med. Chem. 37, 3977-3985.
22. Van der Hoeven, T. A., and Coon, M. (1974) Preparation and properties of partially purified cytochrome P-450 and reduced nicotinamide adenine dinucleotide phosphate P-450 reductase from rabbit liver microsomes. J. Biol. Chem. 249, 6302-6310.
23. Smith, P. K., Krohn, R. I., Hermanson, G. T., Mallia, A. K., Gartner, F. H., Provenzano, M. D., Fujimoto, E. K., Goeke, N. M., Olson, B. J., and Klenk, D. C. (1985) Measurement of protein using bicinchoninic acid. Anal. Biochem. 150, 76-85.
24. Omura, T., and Sato, R. (1964) The carbon monoxide-binding pigment of liver microsomes. II. Solubilization, purification, and properties. J. Biol. Chem. 239, 2379-2385.
25. Dieckhaus, C. M., Fernandez-Metzler, C. L., King, R., Krolikowski, P. H., and Baillie, T. A. (2005) Negative ion tandem mass spectrometry for the detection of glutathione conjugates. Chem. Res. Toxicol. 18. 630-638.
26. Smith, K. S., Smith, P. L., Heady, T. N., Trugman, J. M., Harman, W. D., and Macdonald, T. L. (2003) In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem. Res. Toxicol. 16, 123-128.
27. Baillie, T. A., and Davis, M. R. (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol. Mass Spectrom. 22, 319-325.
28. Baillie, T. A., Pearson, P. G., Rashed, M. S., and Howald, W. N. (1989) The use of mass spectrometry in the study of chemically reactive drug metabolites. Application of MS/MS and LC/MS to the analysis of glutathione- and related S-linked conjugates of N-methylformamide. J. Pharm. Biomed. Anal. 7, 1351-1360.
29. Chen, W. G., Zhang, C., Avery, M. J., and Fouda, H. G. (2001) Reactive metabolite screen for reducing candidate attrition in drug discovery. Adv. Exp. Med. Biol. 500, 521-524.
30. He, K., Talaat, R. E., Pool, W. F., Reily, M. D., Reed, J. E., Bridges, A. J. and Woolf, T. F. (2004) Metabolic activation of troglitazone: Identification of a reactive metabolite and mechanisms involved. Drug Metab. Dispos. 32, 639-646.
31. Reddy, V. B., Karanam, B. V., Gruber, W. L., Wallace, M. A., Vincent, S. H., Franklin, R. B., and Baillie, T. A. (2005) Mechanistic studies on the metabolic scission of thiazolidinedione derivatives to acyclic thiols. Chem. Res. Toxicol. 18, 880-888.
32. Tafazoli, S., Spehar, D. D., and O'Brien, P. J. (2005) Oxidative stress mediated idiosyncratic drug toxicity. Drug Metab. Rev. 37, 311-325.
33. Narayanan, P. K., Hart, T., Elcock, F., Zhang, C., Hahn, L., McFarland, D., Schwartz, L., Morgan, D. G., and Bugelski, P. (2003) Troglitazone-induced intracellular oxidative stress in rat hepatoma cells: A flow cytometric assessment. Cytometry A 52, 28-35.
34. Tirmenstein, M. A., Hu, C. X., Gales, T. L., Maleeff, B. E., Narayanan, P. K., Kurali, E., Hart, T. K., Thomas, H. C., and Schwartz, L. W. (2002) Effects of troglitazone on HepG2 viability and mitochondrial function. Toxicol. Sci. 69, 131-138.
35. Funk, C., Ponelle, C., Scheuermann, G., and Pantze, M. (2001) Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: In vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol. Pharmacol. 59, 627-635.